Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough

Area of Science:

• Hepatology
• Immunology
• Critical Care Medicine

Background:

• Acute-on-chronic liver failure (ACLF) is a severe clinical syndrome characterized by acute decompensation of cirrhosis.
• It presents a complex, multifactorial condition with a dynamic course, rapid organ failure, and high short-term mortality.
• Immune system dysregulation is central to ACLF pathogenesis and progression.

Purpose of the Study:

• To summarize the understanding of ACLF pathogenesis, focusing on immune system dynamics.
• To identify emerging therapeutic targets for managing ACLF.
• To highlight the need for further research into novel treatment strategies.

Main Methods:

• Review of current literature on ACLF pathophysiology and immune responses.
• Analysis of the natural course of ACLF, including inflammatory and immune-exhaustion phases.
• Identification of potential therapeutic interventions based on unraveling pathophysiology.

Main Results:

• ACLF involves an initial excessive systemic inflammatory response followed by immuno-exhaustion or immunoparalysis.
• This immune dysregulation drives organ failure, mortality, and susceptibility to secondary infections.
• Potential therapeutic strategies include albumin replacement, TLR4 antagonists, gut microbiota modulation, and FXR agonists.

Conclusions:

• Understanding the immune dysregulation in ACLF is crucial for developing effective management strategies.
• Emerging therapies targeting immune modulation, albumin homeostasis, and gut health show promise for improving ACLF patient outcomes.
• Further clinical studies are warranted to evaluate the efficacy of these novel therapeutic approaches.